Supplementary table 2 A

Aug 17, 2014

10 likes | 81 Views

Supplementary table 2 A.

Share Presentation

Embed Code

Link

supplementary table

spiro

Download Presentation

Supplementary table 2 A

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplementary table 2 A

Supplementary Table 1

Supplementary Table 1. Patient 1 2 3 4 5 6 7 8 9 10 11. Age (y) 44 36 34 40 26 36 35 48 33 48 35. Sex 1 M M M M F M M F M M M. Disease duration (y) 6 11 4 11 8 7 15 14 8 17 5. Disease classification 2 A2 L1 B3p A2 L1 B3p A2 L3 B3

178 views • 1 slides

Supplementary Table 1

Supplementary Table 1. Supplementary Table 2 The results of screening stage analysis of colorectal cancer .

212 views • 9 slides

Supplementary table 1

Supplementary table 1. Supplementary table 2. Supplementary table 3. A. B. Supplementary table 4. Supplementary table 5. Supplementary table 6. A. B. C. Supplementary Fig. S1. A. B. miR-155. c ontrol. siTRF1. miR-155. c ontrol. siTRF1. -. -. +. +. MG132. -. -. +. +.

251 views • 13 slides

Supplementary Table 1

Supplementary Table 1. A.

167 views • 9 slides

Supplementary Table 5

Supplementary Table 5.

81 views • 1 slides

Supplementary table 1.

Supplementary table 1. Strains used in this study. Strain. Genotype. Reference. ho∆ MAT α ::URA3::HOcs hml∆::ADE1 hmr∆::ADE1 ade1-100 leu2-3,112 lys5 trp1::hisG ura3-52 ade3::GAL::HO. SLY19. S. Lee et al. 2003.

100 views • 1 slides

Supplementary Table 1:

Supplementary Table 1:.

90 views • 1 slides

Supplementary table 1

Supplementary table 1. Time after trauma (min). MAP (mmHg). ETCO 2 (mmHg). ICP (mmHg). -10. 79 +/- 14. 37.8 +/- 0.9. 3 +/- 1. +10. 72 +/- 11. 37.6 +/- 0.9. +60. 70 +/- 15. 37.8 +/- 0.5. +120. 66 +/- 12. 37.5 +/- 0.9. +180. 59 +/- 12. 37.7 +/- 0.9. 15 +/- 7.

146 views • 5 slides

Supplementary Table 1

Supplementary Table 1. Primers used for qRT-PCR. Supplementary Table 2.

158 views • 3 slides

Supplementary Table 2.

Supplementary Table 2. a The #CpG indicates the number of CpG in the sequence region. b The plus(+) and minus(-) indicate the presence and absence of CpG island, respectively. c The plus(+) and minus(-) indicate the presence and absence of candidate methylated site, respectively.

475 views • 24 slides

Supplementary table 2

Supplementary table 2.

62 views • 1 slides

Supplementary Table

Supplementary Table.

90 views • 1 slides

Supplementary table 1

Supplementary table 1. Gene-expression values of LM f and LDC in microarray analysis were shown.

124 views • 1 slides

Supplementary Table 1.

Supplementary Table 1. Selected reference drugs, testing concentrations and therapeutic exposure.

283 views • 15 slides

Supplementary Table 2.

67 views • 1 slides

Supplementary table 2.

Supplementary table 2. Association of ARID3B and MYCN expression in specific tumors. ARID3B MYCN. ARID3B and MYCN.

112 views • 1 slides

Supplementary table 2 B

Supplementary table 2 B.

89 views • 1 slides

Supplementary Table S1.

Supplementary Table S1. Primer sequences used for PCR amplification of DDAH1, DDAH2 and tubulin message. Supplementary Figures. s1A. s1B. s1C. s1D.

235 views • 6 slides

Supplementary Table

Antigen. Host. Isotype. Dilution. Source. Ankyrin G. Mouse. IgG1. 1:100. Zymed Labs San Francisco, CA. Caspr. Rabbit. IgG. 1:1000. E. Peles, Israel. Dystrophin. Mouse. IgG1. 1:200. Sigma Missouri, USA. FluoroMyelin green. -. -. 1:400. Molecular Probes Paisley, UK. Kv1.1.

83 views • 1 slides

Supplementary Table 1

Supplementary Table 1. IC50 Value Matrix. Supplementary Table 1: IC 50 value matrix. Each cell line was treated with a dose range of 160 nM up to 1 µM of TAK-733, trametinib or vermurafenib and proliferation was measured using the SRB assay.

170 views • 1 slides

Supplementary Table 1

Supplementary Table 1. Clinical Characteristics of human volunteers. Group I : Normal. Group II : CRS. Supplementary Table 2. Antibodies used for immunofluoresent microscopy. Supplementary Table 3. Antibodies used for mouse flow cytometry.

68 views • 5 slides

Supplementary Table 1

124 views • 11 slides

More Related